BR112017025266A2 - processo para produzir brivaracetam - Google Patents
processo para produzir brivaracetamInfo
- Publication number
- BR112017025266A2 BR112017025266A2 BR112017025266A BR112017025266A BR112017025266A2 BR 112017025266 A2 BR112017025266 A2 BR 112017025266A2 BR 112017025266 A BR112017025266 A BR 112017025266A BR 112017025266 A BR112017025266 A BR 112017025266A BR 112017025266 A2 BR112017025266 A2 BR 112017025266A2
- Authority
- BR
- Brazil
- Prior art keywords
- brivaracetam
- produce
- produce brivaracetam
- Prior art date
Links
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 title 1
- 229960002161 brivaracetam Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
- C07C209/06—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms
- C07C209/08—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of halogen atoms with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/19—Acids containing three or more carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/38—Acyl halides
- C07C53/46—Acyl halides containing halogen outside the carbonyl halide group
- C07C53/50—Acyl halides containing halogen outside the carbonyl halide group of acids containing three or more carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/63—Halogen-containing esters of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C71/00—Esters of oxyacids of halogens
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510271449.6A CN106279074B (zh) | 2015-05-25 | 2015-05-25 | 一种化合物及其制备方法和在合成布瓦西坦中的用途 |
| CN201510430387.9A CN106365986B (zh) | 2015-07-21 | 2015-07-21 | 化合物及其制备方法和在合成布瓦西坦中的用途 |
| CN201510648574.4A CN106432030B (zh) | 2015-10-10 | 2015-10-10 | 布瓦西坦的一种制备方法 |
| CN201610099672 | 2016-02-24 | ||
| PCT/US2016/033965 WO2016191435A1 (en) | 2015-05-25 | 2016-05-24 | Processes to produce brivaracetam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017025266A2 true BR112017025266A2 (pt) | 2018-08-07 |
Family
ID=57394289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017025266A BR112017025266A2 (pt) | 2015-05-25 | 2016-05-24 | processo para produzir brivaracetam |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10221134B2 (https=) |
| EP (1) | EP3302441B1 (https=) |
| JP (1) | JP6872500B2 (https=) |
| KR (1) | KR102630456B1 (https=) |
| BR (1) | BR112017025266A2 (https=) |
| ES (1) | ES2965746T3 (https=) |
| HR (1) | HRP20240027T1 (https=) |
| HU (1) | HUE064612T2 (https=) |
| IL (1) | IL255880B (https=) |
| MX (1) | MX380263B (https=) |
| PL (1) | PL3302441T3 (https=) |
| WO (1) | WO2016191435A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016191435A1 (en) | 2015-05-25 | 2016-12-01 | Peng Wang | Processes to produce brivaracetam |
| CN107056643A (zh) * | 2017-03-01 | 2017-08-18 | 苏州鹏旭医药科技有限公司 | 一种化合物的晶型a及其制备纯化方法 |
| WO2018141276A1 (zh) * | 2017-02-05 | 2018-08-09 | 苏州鹏旭医药科技有限公司 | 布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法 |
| CN108503609B (zh) * | 2017-02-24 | 2019-12-24 | 北京艾百诺医药股份有限公司 | 一种制备光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的方法 |
| CN108503573B (zh) * | 2017-02-24 | 2019-11-22 | 北京艾百诺医药股份有限公司 | 一种布瓦西坦的新的制备方法 |
| CN108689903B (zh) * | 2017-04-06 | 2019-12-24 | 北京艾百诺医药股份有限公司 | 一种布瓦西坦的新的制备方法 |
| US20210163410A1 (en) * | 2017-05-29 | 2021-06-03 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl] butanamide and its intermediates thereof |
| WO2019087172A1 (en) * | 2017-12-19 | 2019-05-09 | Glenmark Pharmaceuticals Limited | Process for preparation of brivaracetam |
| CN108409557A (zh) * | 2018-05-17 | 2018-08-17 | 丽珠集团新北江制药股份有限公司 | 布瓦西坦新中间体及其合成方法和应用 |
| IT201800006320A1 (it) * | 2018-06-14 | 2019-12-14 | Processo per la sintesi asimmetrica di (r)-4-propildiidrofuran-2(3h)-one | |
| CN110615744B (zh) | 2018-06-20 | 2023-01-06 | 上海朴颐化学科技有限公司 | 一种布瓦西坦中间体及其制备方法 |
| US11247977B2 (en) | 2018-06-22 | 2022-02-15 | Fujian Haixi Pharmaceuticals Co., Ltd. | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug |
| US20220064111A1 (en) * | 2019-01-17 | 2022-03-03 | Clininvent Research Pvt. Ltd. | Enantioselective synthesis of brivaracetam and intermediates thereof |
| CN112110843A (zh) * | 2019-06-20 | 2020-12-22 | 北京万全德众医药生物技术有限公司 | 一种布瓦西坦的新制备方法 |
| WO2021260721A1 (en) * | 2020-06-23 | 2021-12-30 | Clininvent Research Pvt. Ltd. | A new cost effective and scalable process for synthesizing pure brivaracetam |
| EP4077278B1 (en) | 2020-12-14 | 2025-03-12 | Alivus Life Sciences Limited | Process for the preparation of brivaracetam |
| US11400074B1 (en) * | 2021-02-01 | 2022-08-02 | Divi's Laboratories Ltd. | Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam |
| US20240343689A1 (en) * | 2021-08-16 | 2024-10-17 | Optimus Drugs Private Limited | Synthesis of brivaracetam |
| CN114634437B (zh) * | 2022-03-29 | 2023-05-30 | 武汉氟本氘合新材料科技有限公司 | 一种布瓦西坦的简易制备方法 |
| US11884623B2 (en) * | 2022-05-23 | 2024-01-30 | Divi's Laboratories Ltd. | Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam |
| CN114989061A (zh) * | 2022-08-03 | 2022-09-02 | 江苏同禾药业有限公司 | 一种布瓦西坦的制备方法 |
| CN115466233B (zh) * | 2022-09-28 | 2024-08-23 | 合肥立方制药股份有限公司 | 一种布瓦西坦中间体（r）-4-丙基-二氢呋喃-2-酮的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| JP4334344B2 (ja) * | 2001-08-10 | 2009-09-30 | ユセベ ファルマ ソシエテ アノニム | オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用 |
| KR101124098B1 (ko) | 2003-09-24 | 2012-03-21 | 유씨비 파마, 에스.에이. | 2-옥소-1-피롤리딘 유도체를 제조하는 방법 |
| TW200724139A (en) * | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| WO2007031263A1 (en) * | 2005-09-15 | 2007-03-22 | Ucb Pharma, S.A. | 4-substituted pyrr0lidin-2-0nes and their use |
| JP2009518335A (ja) | 2005-12-07 | 2009-05-07 | ユセベ ファルマ ソシエテ アノニム | ３−カルボキシ−２−オキソ−１−ピロリジン誘導体及びそれらの使用 |
| US8338621B2 (en) * | 2005-12-21 | 2012-12-25 | Ucb S.A. | Process for the preparation of 2-oxo-1-pyrrolidine derivatives |
| KR20070081959A (ko) | 2006-02-14 | 2007-08-20 | (주)지앤테크 | 은이 포함된 정수기용 필터 |
| KR100846419B1 (ko) | 2007-08-10 | 2008-07-15 | 한국과학기술원 | 프레가발린의 신규한 제조 방법 |
| KR100915671B1 (ko) * | 2007-08-14 | 2009-09-04 | 한국과학기술원 | 치환된 γ-부티로락톤의 광학선택적 제조방법 |
| US20120021469A1 (en) * | 2009-03-27 | 2012-01-26 | Codexis, Inc. | Amidases and methods of their use |
| EP2571352A4 (en) | 2010-05-21 | 2014-09-17 | Sloan Kettering Inst Cancer | SELECTIVE HDAC HEMMER |
| CN103561732A (zh) | 2011-04-11 | 2014-02-05 | 阿克西里亚药品公司 | 治疗化合物 |
| US20140228579A1 (en) | 2013-02-14 | 2014-08-14 | Brock Unviersity | Method for the catalytic reduction of acid chlorides and imidoyl chlorides |
| CN103819389A (zh) * | 2014-02-17 | 2014-05-28 | 北京博泽德润医药科技开发有限公司 | 一种左乙拉西坦制备方法 |
| WO2016191435A1 (en) * | 2015-05-25 | 2016-12-01 | Peng Wang | Processes to produce brivaracetam |
| ES2893301T3 (es) | 2015-11-03 | 2022-02-08 | Ucb Biopharma Sprl | Proceso para preparar brivaracetam |
| US20210163410A1 (en) | 2017-05-29 | 2021-06-03 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl] butanamide and its intermediates thereof |
| WO2019087172A1 (en) | 2017-12-19 | 2019-05-09 | Glenmark Pharmaceuticals Limited | Process for preparation of brivaracetam |
| WO2020148731A1 (en) | 2019-01-19 | 2020-07-23 | Stereokem Pvt. Ltd. | Process for preparation of brivaracetam intermediates and use thereof |
-
2016
- 2016-05-24 WO PCT/US2016/033965 patent/WO2016191435A1/en not_active Ceased
- 2016-05-24 EP EP16800643.5A patent/EP3302441B1/en active Active
- 2016-05-24 KR KR1020177037062A patent/KR102630456B1/ko active Active
- 2016-05-24 ES ES16800643T patent/ES2965746T3/es active Active
- 2016-05-24 US US15/575,373 patent/US10221134B2/en active Active
- 2016-05-24 HU HUE16800643A patent/HUE064612T2/hu unknown
- 2016-05-24 JP JP2017561732A patent/JP6872500B2/ja active Active
- 2016-05-24 BR BR112017025266A patent/BR112017025266A2/pt not_active Application Discontinuation
- 2016-05-24 HR HRP20240027TT patent/HRP20240027T1/hr unknown
- 2016-05-24 MX MX2017015133A patent/MX380263B/es unknown
- 2016-05-24 PL PL16800643.5T patent/PL3302441T3/pl unknown
-
2017
- 2017-11-23 IL IL255880A patent/IL255880B/en active IP Right Grant
-
2019
- 2019-01-24 US US16/256,596 patent/US11673862B2/en active Active
- 2019-01-24 US US16/256,522 patent/US12221413B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018523633A (ja) | 2018-08-23 |
| CA2984832A1 (en) | 2016-12-01 |
| WO2016191435A1 (en) | 2016-12-01 |
| EP3302441B1 (en) | 2023-12-13 |
| IL255880B (en) | 2021-02-28 |
| EP3302441C0 (en) | 2023-12-13 |
| MX2017015133A (es) | 2018-08-01 |
| IL255880A (en) | 2018-01-31 |
| KR102630456B1 (ko) | 2024-01-29 |
| JP6872500B2 (ja) | 2021-05-19 |
| US20190152908A1 (en) | 2019-05-23 |
| US10221134B2 (en) | 2019-03-05 |
| US12221413B2 (en) | 2025-02-11 |
| EP3302441A1 (en) | 2018-04-11 |
| US20180155284A1 (en) | 2018-06-07 |
| PL3302441T3 (pl) | 2024-05-20 |
| US20190152909A1 (en) | 2019-05-23 |
| KR20180012788A (ko) | 2018-02-06 |
| MX380263B (es) | 2025-03-12 |
| HRP20240027T1 (hr) | 2024-04-26 |
| ES2965746T3 (es) | 2024-04-16 |
| US20240199541A9 (en) | 2024-06-20 |
| HUE064612T2 (hu) | 2024-04-28 |
| US11673862B2 (en) | 2023-06-13 |
| EP3302441A4 (en) | 2019-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017025266A2 (pt) | processo para produzir brivaracetam | |
| PT3319952T (pt) | Processo de produção de canabidiol e delta-9-tetrahidrocanabinol | |
| EP3388133A4 (en) | demister | |
| EP3341477A4 (en) | MANIPULATED CRISPR-CAS9 NUCLEASES | |
| PT2970383T (pt) | Processo de tratamento de fibrose | |
| PL3237623T3 (pl) | Wytwarzanie roślin haploidalnych | |
| DK3341479T3 (da) | LNA-G-Proces | |
| DK3242685T3 (da) | Cxcr4-bindende molekyler | |
| BR112016026251A2 (pt) | processo de polimerização em lama para formar polietileno | |
| HUE057118T2 (hu) | Folyamat | |
| PT2953733T (pt) | Processo de pintura | |
| PT3393468T (pt) | Métodos para tratar imunodeficiências | |
| PT3256546T (pt) | Processo de despolimerização | |
| BR112017000829A2 (pt) | processo para acetilação de madeira | |
| BR112016026212A2 (pt) | Processo para preparar cianidrina contendo fósforo | |
| DK3016976T3 (da) | Proces | |
| EP3265120C0 (en) | PROCEDURE | |
| EP3359485C0 (en) | Production of graphene | |
| BR112017027349A2 (pt) | método para melhorar os benefícios de saúde | |
| ES2874374T8 (es) | Proceso para producir hidrógeno | |
| PL3176152T3 (pl) | Sposób wytwarzania mocznika | |
| BR112017010466A2 (pt) | processo para a produção de metildiclorofosfano | |
| BR112016019608A2 (pt) | processo para purificação de polissacarídeos de men-c | |
| BR112016030604A2 (pt) | Processo para preparação de ácidos 3- hidroxipicolínicos | |
| BR112016008906A2 (pt) | Processo para preparar metil metacrilato |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023015468-1 PROTOCOLO 870230067536 EM 01/08/2023 15:40. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09R | Decision of refusal: republication [chapter 9.2.3 patent gazette] |
Free format text: O PRESENTE PEDIDO TEVE UM PARECER DE INDEFERIMENTO NOTIFICADO NA RPI NO 2753 DE 10/10/2023, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECOES (ERROS DE DIGITACAO), ASSIM REPUBLICO A REFERIDA PUBLICACAO. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: SUZHOU PENGXU PHARMATECH CO., LTD. (CN) |